Abstract
Background: Recent years have witnessed a huge shift in the management and prognosis of metastatic prostate cancer with the advent of new-generation anti-hormonal treatments. Docetaxel, which was initially approved in the castrate-resistant prostate cancer setting, has been approved in the earlier course of the disease as it is still castrate sensitive. Summary: Apart from cabazitaxel and in the absence of other effective chemotherapies, docetaxel rechallenge (DR) in patients with proved sensitivity to docetaxel in the earlier stage of the disease remains a possible option. Unfortunately, the pivotal trials rarely reported on the outcomes of docetaxel retreatment which seems a plausible option in patients initially responding to docetaxel and maintaining a minimum progression-free interval of 3–6 months. In this review, a summary of the clinical evidence and potential concerns for the use of DR in patients with metastatic prostate cancer will be presented. Key Messages: Pivotal trials of docetaxel in metastatic castrate-sensitive prostate cancer as well as metastatic castrate-resistant prostate cancer have not reported on the outcomes of DR except in the GETUG-AFU 15 trial where the outcomes were disappointing. Based on the published retrospective data, DR may be effective in patients who initially responded to docetaxel and maintained a progression-free interval exceeding 6 months.
Journal Section:
Review Article
References
1.
Siegel
RL
, Miller
KD
, Jemal
A
. Cancer statistics, 2019
. CA Cancer J Clin
. 2019
Jan
;69
(1
):7
–34
.
[PubMed]
0007-92352.
Davies
A
, Conteduca
V
, Zoubeidi
A
, Beltran
H
. Biological evolution of castration-resistant prostate cancer
. Eur Urol Focus
. 2019
Mar
;5
(2
):147
–54
.
[PubMed]
2405-45693.
Dellis
A
, Zagouri
F
, Liontos
M
, Mitropoulos
D
, Bamias
A
, Papatsoris
AG
, et al. Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations
. Cancer Treat Rev
. 2018
.
[PubMed]
0305-73724.
de Bono
JS
, Logothetis
CJ
, Molina
A
, Fizazi
K
, North
S
, Chu
L
, et al; COU-AA-301 Investigators
. Abiraterone and increased survival in metastatic prostate cancer
. N Engl J Med
. 2011
May
;364
(21
):1995
–2005
.
[PubMed]
0028-47935.
de Bono
JS
, Oudard
S
, Ozguroglu
M
, Hansen
S
, Machiels
JP
, Kocak
I
, et al; TROPIC Investigators
. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
. Lancet
. 2010
Oct
;376
(9747
):1147
–54
.
[PubMed]
0140-67366.
Scher
HI
, Fizazi
K
, Saad
F
, Taplin
ME
, Sternberg
CN
, Miller
K
, et al; AFFIRM Investigators
. Increased survival with enzalutamide in prostate cancer after chemotherapy
. N Engl J Med
. 2012
Sep
;367
(13
):1187
–97
.
[PubMed]
0028-47937.
Kantoff
PW
, Higano
CS
, Shore
ND
, Berger
ER
, Small
EJ
, Penson
DF
, et al; IMPACT Study Investigators
. Sipuleucel-T immunotherapy for castration-resistant prostate cancer
. N Engl J Med
. 2010
Jul
;363
(5
):411
–22
.
[PubMed]
0028-47938.
Parker
C
, Nilsson
S
, Heinrich
D
, Helle
SI
, O’Sullivan
JM
, Fosså
SD
, et al; ALSYMPCA Investigators
. Alpha emitter radium-223 and survival in metastatic prostate cancer
. N Engl J Med
. 2013
Jul
;369
(3
):213
–23
.
[PubMed]
0028-47939.
Sweeney
C
, Chen
YH
, Liu
G
, Carducci
M
, Jarrard
D
, Eisenberger
M
, et alLong term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial
. European Society for Medical Oncology
; 2016
. 10.
James
ND
, Sydes
MR
, Clarke
NW
, Mason
MD
, Dearnaley
DP
, Spears
MR
, et al; STAMPEDE investigators
. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
. Lancet
. 2016
Mar
;387
(10024
):1163
–77
.
[PubMed]
0140-673611.
Tucci
M
, Caffo
O
, Buttigliero
C
, Cavaliere
C
, D’aniello
C
, Di Maio
M
, et al. Therapeutic options for first-line metastatic castration-resistant prostate cancer: suggestions for clinical practise in the CHAARTED and LATITUDE era
. Cancer Treat Rev
. 2019
Mar
;74
:35
–42
.
[PubMed]
0305-737212.
Tannock
IF
, de Wit
R
, Berry
WR
, Horti
J
, Pluzanska
A
, Chi
KN
, et al; TAX 327 Investigators
. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
. N Engl J Med
. 2004
Oct
;351
(15
):1502
–12
.
[PubMed]
0028-479313.
Petrylak
DP
, Tangen
CM
, Hussain
MH
, Lara
PN
Jr, Jones
JA
, Taplin
ME
, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
. N Engl J Med
. 2004
Oct
;351
(15
):1513
–20
.
[PubMed]
0028-479314.
Berthold
DR
, Pond
GR
, Soban
F
, de Wit
R
, Eisenberger
M
, Tannock
IF
. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
. J Clin Oncol
. 2008
Jan
;26
(2
):242
–5
.
[PubMed]
0732-183X15.
Gravis
G
, Fizazi
K
, Joly
F
, Oudard
S
, Priou
F
, Esterni
B
, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
. Lancet Oncol
. 2013
Feb
;14
(2
):149
–58
.
[PubMed]
1470-204516.
Sweeney
CJ
, Chen
YH
, Carducci
M
, Liu
G
, Jarrard
DF
, Eisenberger
M
, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
. N Engl J Med
. 2015
Aug
;373
(8
):737
–46
.
[PubMed]
0028-479317.
Gravis
G
, Boher
JM
, Joly
F
, Soulié
M
, Albiges
L
, Priou
F
, et al; GETUG
. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial
. Eur Urol
. 2016
Aug
;70
(2
):256
–62
.
[PubMed]
0302-283818.
Seruga
B
, Ocana
A
, Tannock
IF
. Drug resistance in metastatic castration-resistant prostate cancer
. Nat Rev Clin Oncol
. 2011
Jan
;8
(1
):12
–23
.
[PubMed]
1759-477419.
Beer
TM
, Armstrong
AJ
, Rathkopf
DE
, Loriot
Y
, Sternberg
CN
, Higano
CS
, et al; PREVAIL Investigators
. Enzalutamide in metastatic prostate cancer before chemotherapy
. N Engl J Med
. 2014
Jul
;371
(5
):424
–33
.
[PubMed]
0028-479320.
Ryan
CJ
, Smith
MR
, de Bono
JS
, Molina
A
, Logothetis
CJ
, de Souza
P
, et al; COU-AA-302 Investigators
. Abiraterone in metastatic prostate cancer without previous chemotherapy
. N Engl J Med
. 2013
Jan
;368
(2
):138
–48
.
[PubMed]
0028-479321.
Suzman
DL
, Luber
B
, Schweizer
MT
, Nadal
R
, Antonarakis
ES
. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone
. Prostate
. 2014
Sep
;74
(13
):1278
–85
.
[PubMed]
0270-413722.
Mezynski
J
, Pezaro
C
, Bianchini
D
, Zivi
A
, Sandhu
S
, Thompson
E
, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance
. Ann Oncol
. 2012
Nov
;23
(11
):2943
–7
.
[PubMed]
0923-753423.
Schweizer
MT
, Zhou
XC
, Wang
H
, Bassi
S
, Carducci
MA
, Eisenberger
MA
, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer
. Eur Urol
. 2014
Oct
;66
(4
):646
–52
.
[PubMed]
0302-283824.
Oudard
S
, Kramer
G
, Caffo
O
, Creppy
L
, Loriot
Y
, Hansen
S
, et al. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer
. BJU Int
. 2015
May
;115
(5
):744
–52
.
[PubMed]
1464-409625.
Petrioli
R
, Roviello
G
, Fiaschi
AI
, Laera
L
, Miano
ST
, De Rubertis
G
, et al. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience
. Med Oncol
. 2015
Mar
;32
(3
):52
.
[PubMed]
1357-056026.
Di Lorenzo
G
, Figg
WD
, Fossa
SD
, Mirone
V
, Autorino
R
, Longo
N
, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study
. Eur Urol
. 2008
Nov
;54
(5
):1089
–94
.
[PubMed]
0302-283827.
Bouman-Wammes
EW
, van den Berg
HP
, de Munck
L
, Beeker
A
, Smorenburg
CH
, Vervenne
WL
, et al. A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: the RECARDO trial
. Eur J Cancer
. 2018
Feb
;90
:1
–9
.
[PubMed]
0959-804928.
Caffo
O
, Pappagallo
G
, Brugnara
S
, Caldara
A
, di Pasquale
MC
, Ferro
A
, et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors
. Urology
. 2012
Mar
;79
(3
):644
–9
.
[PubMed]
0090-429529.
Mountzios
I
, Bournakis
E
, Efstathiou
E
, Varkaris
A
, Wen
S
, Chrisofos
M
, et al. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer
. Urology
. 2011
Mar
;77
(3
):682
–7
.
[PubMed]
0090-429530.
Li
YF
, Zhang
SF
, Zhang
TT
, Li
L
, Gan
W
, Jia
HT
, et al. Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison
. Asian J Androl
. 2013
Nov
;15
(6
):773
–9
.
[PubMed]
1008-682X31.
Miller
K
, Wulfing
C
, Lehmann
J
, Johannsen
M
, Heidenreich
A
, Hegele
A
, et al Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition: Preliminary results of a multicenter Phase II study (AUO AP33/02). J Clin Oncol. 2005
;23(16_suppl):4613–4613.32.
Cash
H
, Steiner
U
, Heidenreich
A
, Klotz
T
, Albers
P
, Melchior
S
, et al; PRINCE investigators
. Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE)
. BJU Int
. 2018
Nov
;122
(5
):774
–82
.
[PubMed]
1464-409633.
Di Lorenzo
G
, Buonerba
C
, Faiella
A
, Rescigno
P
, Rizzo
M
, Autorino
R
, et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
. BJU Int
. 2011
Jan
;107
(2
):234
–9
.
[PubMed]
1464-409634.
Eymard
JC
, Oudard
S
, Gravis
G
, Ferrero
JM
, Theodore
C
, Joly
F
, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
. BJU Int
. 2010
Oct
;106
(7
):974
–8
.
[PubMed]
1464-409635.
Loriot
Y
, Massard
C
, Gross-Goupil
M
, Di Palma
M
, Escudier
B
, Bossi
A
, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
. Eur J Cancer
. 2010
Jul
;46
(10
):1770
–2
.
[PubMed]
0959-804936.
Thomas
C
, Brandt
MP
, Baldauf
S
, Tsaur
I
, Frees
S
, Borgmann
H
, et al. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival
. Int Urol Nephrol
. 2018
Oct
;50
(10
):1821
–7
.
[PubMed]
0301-162337.
Heck
MM
, Thalgott
M
, Retz
M
, Wolf
P
, Maurer
T
, Nawroth
R
, et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer
. BJU Int
. 2012
Dec
;110
(11 Pt B
11b
):E635
–40
.
[PubMed]
1464-409638.
Lavaud
P
, Gravis
G
, Foulon
S
, Joly
F
, Oudard
S
, Priou
F
, et al. Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial
. Eur Urol
. 2018
May
;73
(5
):696
–703
.
[PubMed]
0302-2838© 2020 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2020
You do not currently have access to this content.
